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This study investigates the use of 18F-fluoromisonidazole (FMISO) PET-guided radiotherapy 
dose painting for potentially overcoming the radioresistant effects of hypoxia in head and 
neck squamous cell carcinoma (HNSCC). 
 
Material and Methods 
 
The study cohort consisted of eight patients with HNSCC who were planned for definitive 
radiotherapy. Hypoxic subvolumes were automatically generated on pre-radiotherapy FMISO 
PET scans. Three radiotherapy plans were generated for each patient: a standard (STD) 
radiotherapy plan to a dose of 70 Gy, a uniform dose escalation (UDE) plan to the standard 
target volumes to a dose of 84 Gy, and a hypoxia dose-painted (HDP) plan with dose 
escalation only to the hypoxic subvolume to 84 Gy. Plans were compared based on tumor 
control probability (TCP), normal tissue complication probability (NTCP), and 




The mean TCP increased from 73% with STD plans to 95% with the use of UDE plans (p < 
0.001) and to 93% with HDP plans (p < 0.001). The mean parotid NTCP increased from 26% 
to 44% with the use of UDE plans (p = 0.003), and the mean mandible NTCP increased from 
2% to 27% with the use of UDE plans (p = 0.001). There were no statistically significant 
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differences between any of the NTCPs between the STD plans and HDP plans. The mean 
UTCP increased from 48% with STD plans to 66% with HDP plans (p = 0.016) and dropped 




Hypoxia-targeted radiotherapy dose painting for head and neck cancer using FMISO PET is 
technically feasible, increases the TCP without increasing the NTCP, and increases the 
UTCP. This approach is superior to uniform dose escalation. 
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Tumor hypoxia is associated with a poor response to radiotherapy. Experiments in malignant 
cell cultures have shown that under hypoxic conditions, approximately three times the 
radiotherapy dose is required to produce equivalent biological effect [1]. Clinical studies have 
also confirmed in head and neck cancer patients that hypoxia is correlated with poorer 
outcomes in terms of locoregional control, disease-free survival, and overall survival [2]. 
 
Several strategies have been developed and tested in large prospective trials to overcome the 
negative effects of hypoxia, including hyperbaric oxygen, carbogen and nicotinamide, 
hemoglobin modification, hypoxic radiosensitizers, and hypoxic cell cytotoxins [1]. A 
metaanalysis has shown that overall, hypoxic modification can improve outcomes in terms of 
locoregional control, disease specific survival and overall survival [3]. 
 
One emerging strategy to overcome hypoxia is the use of functional imaging to identify the 
hypoxic subvolume within tumors for the purposes of radiotherapy dose escalation. This 
strategy emerged partly due to the observation that following radiotherapy for head and neck 
cancers, locoregional recurrences tend to occur “in-field”, in volumes that received the 
highest radiotherapy doses, possibly due to the presence of hypoxic cells [4, 5]. If the hypoxic 
- and therefore more radioresistant - subvolume can be identified, delivering a higher dose of 
radiation to this subvolume may overcome the radioresistance. 
 
Past studies have demonstrated the ability of functional imaging such as 18F-
fluoromisonidazole (FMISO) PET to identify subvolumes of increased hypoxia within 
tumors [6, 7]. FMISO PET has been shown to correlate better with hypoxia [6] than the more 
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widely available 18F-fluorodeoxyglucose (FDG) PET, therefore this was chosen as the 
imaging modality for identifying hypoxia in this study. 
 
A Monte Carlo modeling study of the effects of transient and chronic hypoxia has shown that 
a modest radiotherapy boost dose (120 – 150% of the primary dose) to the hypoxic 
subvolume increases tumor control probability (TCP) back to that found in the absence of 
hypoxia [8]. 
 
The main difficulty in delivering boost doses however, is the possibility of increasing normal 
tissue toxicity due to the proximity of multiple sensitive organs at risk (OAR) to the target 
volumes. This difficulty can potentially be overcome through the use of “dose painting”, 
which employs IMRT to deliver heterogeneous dose distributions to specific subvolumes 
within the tumor, while sparing surrounding organs at risk. 
 
This study investigates the use of FMISO PET scans in identifying hypoxic subvolumes for 
the purposes of designing dose-painted radiotherapy plans. Hypoxia dose painted (HDP) 
radiotherapy plans are compared with standard radiotherapy plans and uniform dose 
escalation (UDE) plans. UDE plans illustrate what kind of results can be expected if dose 
escalation is given to the entire high dose planning target volume (PTV) without using 
FMISO PET guidance. Plans are compared based on their ability to achieve target objectives 
and normal tissue dose constraints, and calculations of TCP, normal tissue complication 
probability (NTCP), and uncomplicated tumor control probability (UTCP). 
 






The study cohort consisted of eight patients with primary head and neck squamous cell 
carcinoma (HNSCC) who had FMISO PET scans prior to definitive radiotherapy. All patients 
recruited into this study had previously untreated HNSCC and had good performance status 
(ECOG < 2). No patient was entered into the study who had received prior surgery or 
radiotherapy for their HNSCC, had symptomatic or radiological evidence of distant 
metastatic disease, was being treated with other anti-cancer therapy, or had a medical 
condition that would compromise the safe delivery of radiotherapy. This prospective study 
was approved by the Austin Health Human Research Ethics Committee. The patient 
characteristics are listed in Table 1. 
 
All patients underwent standard diagnostic and staging investigations including physical 
examination, endoscopic examination, endoscopically-guided biopsy, CT, and FDG PET/CT. 
Pre-radiotherapy FMISO PET scans and radiotherapy planning CT scans were done within 2 
weeks of starting radiotherapy. Following these investigations, the patients underwent 
radiotherapy with or without concurrent chemotherapy according to standard departmental 
protocols.  
 
FMISO PET protocol 
 
The FMISO was prepared in-house using a cyclotron, as previously described [7, 9]. FMISO 
PET studies were acquired on an Allegro GSO-based full-ring PET scanner (Philips 
Healthcare, Cleveland, OH, USA). These were performed in three-dimensional (3D) 
detection mode with a transaxial spatial resolution of 5 mm full width at half maximum 
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(FWHM). Patients were scanned two hours after intravenous injection of approximately 370 
MBq of FMISO. Patient positioning was identical to that of the radiotherapy planning CT 
scan with immobilization using a neck support and a thermoplastic mask extending to the 
shoulders. For each patient a short transmission scan covering the patient’s head and neck 
region was acquired using a single rotating 137Cs point source (740 MBq) for attenuation 
correction. Following this, a PET emission scan of the same region was acquired in three bed 
positions of 6 mins each and reconstructed using a 3D row action maximum likelihood 
iterative algorithm (3D-RAMLA). The image voxel size after reconstruction is 4mm × 4mm 
× 4mm. The FMISO PET scan was co-registered with the radiotherapy planning CT scan 




Standard target volumes were manually contoured. The Gross Tumor Volume (GTV) was 
defined as gross demonstrable tumor using all available diagnostic and staging examinations 
and investigations excluding the FMISO PET scan. The Clinical Target Volume (CTV) was 
defined as the volume of tissue containing the GTV and subclinical malignant disease 
extension. Depending on the clinical scenario the CTV was split into high risk and low risk 
CTVs. Three Planning Target Volumes (PTVs) were generated: PTV1, PTV2 and PTV3. 
These were generated by 5 mm isotropic expansions around the low risk CTV, high risk CTV 
and GTV, respectively. 
 
The hypoxic GTV (GTVH) was defined as the hypoxic subvolume within the GTV 
containing a significant number of hypoxic clonogens. A previous study showed that hypoxic 
tumors  (pO2 < 5 - 10 mmHg) corresponded to a tumor to muscle standardized uptake value 
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(SUV) ratio of approximately 1.5 [6]. The GTVH was therefore automatically generated 
using Mim Maestro (MIM Software Inc., Cleveland, OH, USA) by applying a sub-
thresholding algorithm within the GTV with a tumor to muscle SUV ratio of greater than 1.5 
on the FMISO PET scan (see Figure. 1A). The ipsilateral nuchal muscles were used as the 
reference muscle tissue. A hypoxic PTV (PTVH) was generated by applying a 3 mm 
isotropic expansion margin around the GTVH. 
 
Step-and-shoot IMRT plans were created using 7 or 9 equally spaced fields using the Monaco 
3.0 (Elekta CMS Software, St Louis, MO, USA) treatment planning system. Biologically-
based optimization was employed, and X-ray Voxel Monte Carlo algorithms were used to 
calculate dose. Three radiotherapy plans were created for each patient: a standard (STD) plan, 
a hypoxia dose-painted (HDP) plan, and a uniform dose escalation (UDE) plan. The STD 
plan consisted of a simultaneous integrated boost with 3 dose levels: 56 Gy, 63 Gy and 70 
Gy, prescribed to the PTV1, PTV2 and PTV3, respectively. The HDP plan consisted of the 
same dose levels as the standard plan, as well as a dose of 84 Gy prescribed to the PTVH. 
The UDE plan consisted of a simultaneous integrated boost with 3 dose levels: 56 Gy, 63 Gy 
and 84 Gy, prescribed to the PTV1, PTV2 and PTV3, respectively. The treatment was 
planned to be given over 35 fractions for all plans. The highest dose level of 84 Gy was 
chosen based on a Monte Carlo modeling study which showed that 120 – 150% of the 
primary dose is required to negate the detrimental effects of hypoxia on the TCP [8]. Target 
volume objectives and OAR constraints were derived from the Radiation Therapy and 
Oncology Group (RTOG) 0615 protocol [10] (see Table 2). If significant portions of the PTV 
extended outside of the patient contour, the evaluation of target coverage was made based on 
contours clipped at the patient surface. Planning organ at risk volumes (PRVs) were created 






The tumor control probability (TCP) was calculated according to the Poisson TCP model [11] 
with modifications for additional radiobiological parameters [12] (see equations 1 – 5 in 
Appendix A). The following parameters were used : α/β = 10, α = 0.396, σα= 0.07, 
clonogenic cell density (ρ)= 107 clonogens/cm3, kickoff time (Tk) = 28 days, potential 
doubling time (Tpot) = 3 days [12], sensitiser enhancement ratio (SER) = 1.1 [13]. Within the 
GTVH volume, the oxygen enhancement ratio (OER) was defined as 1.5 [14]; and within the 
GTV (excluding the GTVH), no OER adjustment was made. The OER was then used to 
calculate the hypoxic α value as described in equations 4 and 5 in Appendix A. This 
dichotomous grouping of clonogens into hypoxic and non-hypoxic follows the methodology 
used in previous hypoxia modeling studies [12, 14].  
 
The normal tissue complication probability (NTCP) was calculated using the Lyman-
Kutcher-Burman model [15] with corrections for dose-per-fraction. The following parameters 
were used: n = 1.0, m = 0.53, TD50 = 31.4 Gy, α/β = 3 Gy for the parotid glands [16], n = 
0.07, m = 0.10, TD50 = 72 Gy, α/β = 2 Gy for the mandible, n = 0.05, m = 0.17, TD50 = 66.5 
Gy, α/β = 2 Gy for the spinal cord, and n = 0.16, m = 0.14, TD50 = 65 Gy, α/β = 2.5 Gy for 
the brainstem [1, 15]. 
 
The uncomplicated tumor control probability (UTCP) was calculated using the formula as 




Biological modelling indices (TCP, NTCP and UTCP) were compared using two-way 
analysis of variance (ANOVA) with patient and plan as blocking factors. Pairs of means were 
compared with least significant difference. Statistical tests were performed using SPSS 




In all 24 radiotherapy plans generated, the target volume objectives were met. All STD and 
HDP plans were within all OAR constraints, however only one out of eight UDE plans 
(Patient 1) were within all OAR constraints. For UDE plans, five out of eight patients 
exceeded mandible constraints, and seven out of eight patients exceeded parotid constraints. 
Dose distributions for a STD plan, a HDP plan and a UDE plan for a representative patient 
are shown in Figure 1 and the dose volume histograms (DVH) for that patient are shown in 
Figure 2. 
 
The mean TCPs were 73%, 93%, and 94% for STD plans, HDP plans and UDE plans, 
respectively. HDP plans had a 27% higher TCP than STD plans and the two plans were 
statistically significantly different (p < 0.001). UDE plans had a 29% higher TCP than 
standard plans and the two plans were statistically significantly different (p < 0.001). There 
was no statistically significant difference between HDP plans and UDE plans (p = 0.166). 
The TCPs and UTCPs for each patient are listed in Table 3. 
 
The mean parotid NTCPs were 26%, 26%, and 44% for STD plans, HDP plans and UDE 
plans, respectively. UDE plans had a 71% higher (p = 0.03) parotid NTCP than STD plans, 
12 
 
and a 68% higher (p = 0.03) parotid NTCP than HDP plans. There was no statistically 
significant difference in parotid NTCPs between STD and HDP plans (p = 0.938). 
 
The mean mandible NTCPs were 1%, 2%, and 27% for STD plans, HDP plans and UDE 
plans, respectively. UDE plans had a 15 times higher (p = 0.001) mandible NTCP than STD 
plans, and a 13 times higher (p = 0.001) mandible NTCP than HDP plans. There was no 
statistically significant difference in mandible NTCPs between STD and HDP plans (p = 
0.969). 
 
There were no statistically significant differences in NTCP between standard plans, HDP 
plans, and UDE plans for the spinal cord (p = 0.174) and brainstem (p = 0.529). The NTCPs 
for each patient are listed in Table 4. 
 
The mean UTCPs were 48%, 66% and 37% for STD plans, HDP plans and UDE plans, 
respectively. HDP plans had a 38% higher UTCP than STD plans, and the two plans were 
statistically significantly different (p = 0.016). HDP plans had a 75% higher UTCP than UDE 
plans, and the two plans were statistically significantly different (p = 0.001). There were no 




All STD and HDP plans were within all normal tissue constraints, however not all UDE plans 
were within all normal tissue constraints. Compared with STD plans, HDP plans had higher 
TCP, comparable NTCP, and overall higher UTCP. Compared with STD plans, UDE plans 
also had higher TCP, but had worse NTCP, and therefore tended towards having a worse 
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UTCP. Overall, these results show that HDP plans may improve the therapeutic ratio, 
whereas UDE plans may actually worsen the therapeutic ratio, as they are limited by 
increased toxicity. These results support the strategy of using FMISO PET-guided dose 
painting over undirected dose escalation. 
 
Similar to our study, previous planning studies have shown that boosts to hypoxic 
subvolumes are technically feasible and improve biological modeling indices.  Thorwarth et 
al. [18] performed a planning study with biological modeling on 13 patients with HNSCC, 
comparing three different treatment plans: standard plans to a dose of 70 Gy in 35 fractions, 
uniform dose escalation plans to a dose of 77 Gy in 35 fractions, and hypoxia “dose painting 
by numbers” plans with variable dose prescriptions, up to a maximum of 2.4 Gy per fraction. 
TCPs increased from 55.9% with standard plans to 57.7% with uniform dose escalation plans, 
to 70.2% with hypoxia “dose painting by numbers” plans. The same equivalent uniform dose 
constraints for OARs were used for all the plans, however the exact constraints were not 
described and NTCPs were not calculated. This makes it difficult to assess the level of 
toxicity that would have been associated with these plans. Hendrickson et al. [19] performed 
a planning study on 10 patients with HNSCC, comparing standard radiotherapy to 70 Gy in 
35 fractions with HDP plans to 80 – 90 Gy. HDP plans were associated with a mean 17% 
increase in TCP. Mean NTCPs were also increased with HDP plans; however this was 
described as “clinically acceptable”. A UTCP metric was not used; therefore the overall 
benefit was not fully evaluated. 
 
Our study builds on top of the previously performed studies in a number of ways. We have 
included a third comparison plan with a UDE to the same dose as the HDP plan, which 
proves that any improvements in biological modeling indices are not purely a function of 
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using higher doses. We have also performed GTVH contouring using automatic contouring 
with validated and clearly defined parameters, which ensures that our methodology is 
reproducible. Finally, we have provided a quantitative way to assess the therapeutic ratio in 
the form of the UTCP metric. 
 
There are a few caveats to modeling hypoxia that should be considered when interpreting our 
results. Firstly, hypoxia within tumors has been shown to be dynamic, reflecting its acute and 
chronic components, and also reoxygenation following treatment [1]. The dynamic nature of 
hypoxia can be both an advantage and a disadvantage for HDP strategies. The main 
disadvantage is that if hypoxia is defined based on a single pre-treatment FMISO scan (as in 
this study), it may not be completely reflective of the actual hypoxia present in the tumor at 
each fraction of radiotherapy. If the hypoxia changes significantly during the treatment, our 
study may overestimate the benefits of a HDP plan. Reassuringly, Lin et al. showed that a 
dose painted radiotherapy plan prescribed to the initial hypoxic subvolume still results in 
significantly increased EUDs when applied to a scan done at a separate time point [20] and, 
Eschmann et al. showed that hypoxic volumes tend to shrink as defined on serial FMISO 
scans during radiotherapy, reflecting reoxygenation [21]. A possible advantage to the 
dynamic nature of hypoxia that can be exploited in future studies would be that the changing 
hypoxic volumes can be tracked with multiple FMISO PET scans during treatment, and the 
radiotherapy plan can be adapted to reflect these changes. Potentially, the high dose volumes 
may change locations during a course of treatment, and thus ensure that adjacent sensitive 
normal tissues such as mucosa do not become overdosed. This would be an interesting 




Secondly, hypoxia has substantial spatial variation, with steep oxygen gradients demonstrated 
over distances of only a few cell diameters, which is beyond the resolution of any non-
invasive imaging modality [1]. This means that our study (or any imaging-based study) will 
be unable to detect every single hypoxic clonogen. However, it should still allow the 
identification of significant concentrations of hypoxic clonogens, which still has the greatest 
impact on TCP. 
 
Thirdly, hypoxia has been shown to cause many more deleterious effects than just increased 
radioresistance. For instance, tumors often adapt to hypoxic environments by upregulation of 
hypoxia-inducible factor 1 (HIF-1), which regulates the transcriptional induction of more 
than 100 different known genes [1]. These target genes regulate multiple tumor 
characteristics that confer not only increased radioresistance but also increased angiogenesis, 
metabolism, invasion, and metastasis. The HDP strategy and the biological modeling used in 
this study only address the increased radioresistance, and do not address these other 
aggressive characteristics of hypoxic tumors. As such, this study probably oversimplifies the 
effects of hypoxia. However, even such a simplification provides important insights for future 
research. 
Fourthly, uncertainties related to the delivery of the HDP plan must be considered. There are 
the random and systematic errors associated with patient positioning and patient movement 
that are present with any delivery of radiotherapy, and these are adequately dealt with using 
the PTV margins. There are errors in defining the hypoxic volume as described above which 
may lessen the advantages of dose painting. There are also errors associated with the co-
registration of FMISO PET with the planning CT. Because of the high clinical workload on 
the combined PET/CT scanner in our department, only the single modality PET scanner was 
available for use in this research protocol. The FMISO PET scans were co-registered to the 
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planning CT scans using manual rigid body transformation which introduces additional error. 
If a combined PET/CT scan was performed instead, the manual registration step could 
potentially be eliminated, and the uncertainty would be considerably reduced. This is 
something which needs to be considered for future clinical studies. For the purposes of this 
biological modeling study which is designed to prove the feasibility of HDP, the registration 
error should not change the final results. 
 
Lastly, the findings in this study are based on biological modeling only, which is known to 
have many limitations. The UTCP model is highly controversial because it assumes that 
increases in TCP are equivalent to decreases in NTCP and vice versa. This is an overly 
simplistic model that does not take the relative importance of the different kinds of tumor 
control and normal tissue toxicity endpoints into account. Moreover, very different results 
can potentially be obtained by using different models or different model parameters. As such, 
these results need to be proven in a prospective clinical trial before any firm conclusions can 
be drawn. 
 
Evidence is now accumulating to justify a clinical trial on HDP in HNSCC. As outlined 
previously, there is ample evidence for hypoxia being associated with poorer outcomes after 
radiotherapy [2], and there is now also level 1a evidence for a benefit with hypoxic 
modification in patients with HNSCC [3]. Studies of conventional radiotherapy have shown 
that locoregional recurrences tend to occur “in-field”, in volumes that received the highest 
radiotherapy doses, possibly due to the presence of hypoxic cells [4]. Our study shows that 
dose-painted radiotherapy based on FMISO PET scans are technically feasible, have clear 
benefits in terms of increasing the TCP without increasing the NTCP, and therefore should be 
tested in clinical trials. An FMISO PET-based HDP plan as described in this study should be 
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safe to deliver as evidenced by our biological modeling, as well as by previous clinical trials 
of FDG PET scan-based dose painting, which have been safely delivered to more than 60 
patients with HNSCC to doses as high as 85.9 Gy with acceptable toxicity at early 
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Appendix A. Biological modeling equations 
 
Readers are encouraged to read the original papers that described these equations in order to 
understand their derivation and limitations. The following is a brief summary of the equations 




The TCP was calculated according to the classically described equations for the Poisson TCP 
model [11] with modifications for SER as described by Avanzo et al. [12]: 
𝑇𝐶𝑃 = ∑ 𝑔𝑖(𝜎𝛼) ∙ 𝑇𝐶𝑃(𝛼𝑖, 𝛽𝑖)𝑖        (1) 
𝑇𝐶𝑃(𝛼𝑖, 𝛽𝑖) = ∏ 𝑇𝐶𝑃(𝛼𝑖 , 𝛽𝑖, 𝐷𝑗 , 𝑣𝑗)𝑗   
= ∏ 𝑒𝑥𝑝 [−𝜌𝑐 ∙ 𝑣𝑗 ∙ exp⁡(−𝛼𝑖 ∙ 𝐷𝑗 ∙ 𝑆𝐸𝑅 (1 +
𝛽
𝛼
𝑑𝑗 ∙ 𝑆𝐸𝑅) +
ln⁡(2)
𝑇𝑝𝑜𝑡








2 ]       (3) 
where  and  are radiosensitivity parameters (where  has a Gaussian distribution with 
mean α̅ and standard deviation , representing the variation of  in the population), Dj is the 
dose delivered to a subvolume, vj, ρ is the clonogenic cell density, SER is the sensitiser 
enhancement ratio, T is the overall treatment time, Tk is the kickoff time, and Tpot is the 
potential doubling time. 
 
Linear quadratic radiosensitivity parameters for hypoxic (H) and aerobic (A) cells were  
determined through the following relations [14]: 
𝛼𝐻 =
𝛼𝐴
𝑂𝐸𝑅⁄          (4) 
(𝛼 𝛽⁄ )
𝐻
= (𝛼 𝛽⁄ )
𝐴
∙ 𝑂𝐸𝑅        (5) 




The UTCP was calculated according to the formula defined by Agren et al. [17]: 
𝑈𝑇𝐶𝑃 = 𝑇𝐶𝑃 − 𝑃𝐼 + 𝛿𝑃𝐼(1 − 𝑇𝐶𝑃)       (6) 
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where δ is the statistically independent fraction and PI is the probability of injury. The 
probability of injury is given by 
𝑃𝐼 = 1 −∏ (1 − 𝑁𝑇𝐶𝑃𝑖)
4
𝑖=1         (7) 
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Table 1. Patient characteristics 





1 68 M Larynx T3N2bM0 25.792 2.528 
2 54 M Oropharynx T2N2bM0 52.344 5.352 
3 59 M Hypopharynx T3N1M0 27.296 2.664 
4 43 M Oropharynx T2N1M0 33.52 1.728 
5 57 M Nasopharynx T1N0M0 14.48 1.496 
6 57 M Oropharynx T3N2bM0 24.92 1.14 
7 69 M Oropharynx T3N1M0 21.096 3.312 





Table 2. Target objectives and OAR constraints 
Target objectives  
PTV prescription dose (at each dose level) D95 > prescription dose 
 D99 > 93% of prescription dose 
 D20 < 110% of prescription dose 
 D5 < 115% of prescription dose 
OAR constraint   
Brainstem Dmax < 54 Gy 
Brainstem PRV D1% < 60 Gy 
Spinal cord Dmax < 45 Gy 
Spinal cord PRV D1% < 50 Gy 
Bilat parotids or Dmean < 26 Gy 
  L parotid or Dmean < 20 Gy 
  R parotid Dmean < 20 Gy 




Table 3. TCPs and UTCPs 
Patient 
TCP (%) UTCP (%) 
STD HDP UDE STD HDP UDE 
1 71 93 95 57 73 78 
2 70 92 93 49 71 32 
3 70 92 92 49 67 62 
4 75 93 95 50 69 28 
5 72 94 95 25 50 22 
6 74 95 97 50 77 48 
7 71 91 92 39 49 23 
8 83 94 96 63 71 8 
Mean ± 
SD 73 ± 4 93 ± 1 95 ± 2 48 ± 12 66 ± 10 37 ± 23 
 
The TCPs and UTCPs for each patient are shown. Abbreviations: STD, standard radiotherapy 





Table 4. NTCPs 
 Parotid (%) Mandible (%) Spinal cord (%) Brainstem (%) 
Patient STD HDP UDE STD HDP UDE STD HDP UDE STD HDP UDE 
1 15 20 17 < 1 < 1 < 1 < 1 < 1 < 1 < 1 < 1 < 1 
2 21 22 49 1 < 1 26 < 1 < 1 < 1 < 1 < 1 < 1 
3 238 26 31 < 1 < 1 1 < 1 < 1 < 1 < 1 < 1 < 1 
4 22 19 32 5 7 52 < 1 < 1 < 1 < 1 < 1 < 1 
5 50 43 71 1 1 12 < 1 < 1 < 1 < 1 < 1 < 1 
6 24 18 22 2 1 35 < 1 < 1 < 1 < 1 < 1 < 1 
7 32 41 60 4 2 26 < 1 < 1 < 1 < 1 < 1 < 1 
8 20 20 70 2 4 64 < 1 < 1 < 1 < 1 < 1 < 1 
Mean 26 26 44 2 2 27 < 1 < 1 < 1 < 1 < 1 < 1 
 
The NTCPs for each patient are shown for each organ. Abbreviations: STD, standard 






The FMISO PET/CT scan of a patient with a T3N2b oropharyngeal squamous cell carcinoma 
is shown (A). The GTVH, PTVH, PTV3 and PTV1 are outlined in yellow, green, blue and 
red, respectively. The dose distributions for the STD plan (B), the HDP plan (C) and the UDE 
plan (D) are demonstrated using “colorwash” with red indicating higher doses and blue 





The DVHs are shown for the same patient shown in Figure 1. Solid lines represent the STD 
plan, dashed lines represent the HDP plan, and dotted lines represent the UDE plan. 
 
 
 
